论文部分内容阅读
目的探讨奥沙利铂联合卡培他滨治疗进展期胃癌的临床疗效。方法 80例进展期胃癌患者,根据患者自愿原则分为术前化疗组和正常手术组,各40例。术前化疗组采用奥沙利铂联合卡培他滨的化疗方案进行化疗,正常手术组直接进行手术治疗。观察并记录两组患者术后临床疗效及并发症情况,出院后随访2年统计生存情况。结果术前化疗组患者总缓解率为82.5%,明显高于正常手术组的57.5%,差异具有统计学意义(P<0.05);术前化疗组2年内生存率为87.5%,明显高于正常手术组的67.5%,差异具有统计学意义(P<0.05)。结论奥沙利铂联合卡培他滨治疗进展期胃癌临床疗效显著,无严重并发症及不良反应,患者对药物耐受性较好,能够显著提高患者术后生存及生活质量。
Objective To investigate the clinical efficacy of oxaliplatin plus capecitabine in the treatment of advanced gastric cancer. Methods Eighty patients with advanced gastric cancer were divided into preoperative chemotherapy group and normal operation group according to the voluntary principle of the patients, 40 cases in each. The preoperative chemotherapy group was treated with oxaliplatin combined with capecitabine chemotherapy, and the normal operation group was treated directly. The clinical efficacy and complications of the two groups were observed and recorded. The patients were followed up for 2 years and were followed up for statistical survival. Results The total remission rate in preoperative chemotherapy group was 82.5%, which was significantly higher than that in normal surgery group (57.5%, P <0.05). The 2-year survival rate was 87.5% in preoperative chemotherapy group, which was significantly higher than that in normal group 67.5% of the operation group, the difference was statistically significant (P <0.05). Conclusion Oxaliplatin combined with capecitabine has significant clinical efficacy in the treatment of advanced gastric cancer without serious complications and adverse reactions. Patients are better tolerated with drugs and can significantly improve postoperative survival and quality of life.